Page last updated: 2024-10-30

labetalol and Adrenal Cortex Cancer

labetalol has been researched along with Adrenal Cortex Cancer in 1 studies

Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Enoki, N1
Satoh, Z1
Ogata, A1
Yukioka, H1
Nishimura, K1
Fujimori, M1

Other Studies

1 other study available for labetalol and Adrenal Cortex Cancer

ArticleYear
[Hypertensive response to labetalol in pheochromocytoma].
    Masui. The Japanese journal of anesthesiology, 1984, Volume: 33, Issue:9

    Topics: Adrenal Cortex Neoplasms; Anesthesia, Intravenous; Ethanolamines; Female; Humans; Hypertension; Labe

1984